Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.2 was applied, replacing the previous v3.4.1. No substantive study information or user-facing content was changed.SummaryDifference0.1%

- Check18 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, which does not alter the study details, inclusion criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedMinor UI/text updates: Show glossary and Hide glossary controls were added, along with a new 'Last Update Submitted that Met QC Criteria' label and a Revision: v3.4.0 tag. Wording and capitalization tweaks were made to 'No FEAR Act Data' and 'Last Update Submitted that met QC Criteria'.SummaryDifference0.3%

- Check40 days agoChange DetectedRevision: v3.3.4 was added and the previous Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check68 days agoChange DetectedA new Locations section lists Maryland, North Carolina, and South Carolina, replacing the previous individual location entries. The HHS Vulnerability Disclosure link has been removed, and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.4%

- Check90 days agoChange DetectedAdded a clarifying note that publications are automatically filled from PubMed and updated the revision to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.